Anti-neovasculature preparations for cancer

Abstract

Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of making research models, all of which relate to targeting tumor vasculature.

1 . A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against a first antigen differentially expressed by tumor-associated neovasculature and a second antigen associated with a tumor, wherein the immunization comprises delivering at least a first immunogen corresponding to the first antigen and a second immunogen corresponding to the second antigen.  
     
     
         2 . The method of  claim 1 , wherein the cellular immune response comprises a CTL response.  
     
     
         3 . The method of  claim 1  further comprising the step of detecting the cellular immune response.  
     
     
         4 . The method of  claim 3 , wherein the detecting step comprises detection of tumor growth inhibition, tumor size reduction, inhibition of tumor metastasis, or increase in life expectancy of the mammal.  
     
     
         5 . The method of  claim 3 , wherein the detecting step comprises an assay selected from the group consisting of a cytokine assay, a chromium release assay, an immunofluorescence assay, a cytotoxic T lymphocyte (CTL) assay, an Elispot assay, and observation of the health of the mammal.  
     
     
         6 . A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature, wherein the immunization comprises delivering a first immunogen comprising at least one housekeeping epitope and a second immunogen comprising at least one immune epitope, wherein the housekeeping and immune epitopes are derived from said antigen differentially expressed by tumor-associated neovasculature.  
     
     
         7 . The method of  claim 6 , wherein the first immunogen and the second immunogen are the same.  
     
     
         8 . The method of  claim 6 , further comprising the step of treating the mammal with an anti-tumor therapy active directly against cancerous cells.  
     
     
         9 . The method of  claim 8 , wherein the anti-tumor therapy comprises immunization against a tumor-associated antigen.  
     
     
         10 . The method of  claim 6 , wherein the cellular immune response comprises a CTL response.  
     
     
         11 . The method of  claim 6 , further comprising the step of detecting the cellular immune response.  
     
     
         12 . The method of  claim 11 , wherein the detecting step comprises detection of tumor growth inhibition, tumor size reduction, inhibition of tumor metastasis, or increase in life expectancy of the mammal.  
     
     
         13 . The method of  claim 11 , wherein the detecting step comprises an assay selected from the group consisting of a cytokine assay, a chromium release assay, an immunofluorescence assay, a cytotoxic T lymphocyte (CTL) assay, an Elispot assay, and observation of the health of the mammal.  
     
     
         14 . A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature, wherein the immunization comprises delivering an immunogen comprising at least one housekeeping epitope derived from said antigen differentially expressed by tumor-associated neovasculature.  
     
     
         15 . The method of  claim 14 , wherein the cellular immune response comprises a CTL response.  
     
     
         16 . The method of  claim 14 , further comprising the step of detecting the cellular immune response.  
     
     
         17 . The method of  claim 16 , wherein the detecting step comprises detection of tumor growth inhibition, tumor size reduction, inhibition of tumor metastasis, or increase in life expectancy of the mammal.  
     
     
         18 . The method of  claim 16 , wherein the detecting step comprises an assay selected from the group consisting of a cytokine assay, a chromium release assay, an immunofluorescence assay, a cytotoxic T lymphocyte (CTL) assay, an Elispot assay, and observation of the health of the mammal.